Table 1.
Study groups based on the ATN classification system
| ATN profile (diagnosis) | Study group | N |
|---|---|---|
| A−T−N− (CN)* | Healthy controls | 79 |
| A+T−N− (CN, MCI, AD) | 54 | |
| A+T+N− (CN, MCI, AD) | AD continuum | 64 |
| A+T+N+ (CN, MCI, AD) | 129 | |
| A−T+N− (CN, MCI, AD) | SNAP | 32 |
| A−T+N+ (CN, MCI, AD) | 20 | |
| A−T−N+ (AD) | Non-AD change | 1 |
| A+T− N+ (AD) | Concomitant non-AD change | 1 |
| A−T−N− (MCI, AD) | Normal AD biomarkers | 98 |
Grey fields indicate ADNI participants classified as either healthy controls or patients along the Alzheimer’s continuum, who were included in the study; uncoloured fields indicate ADNI participants who were excluded from the study because of non-Alzheimer’s changes or normal biomarker results despite a diagnosis of MCI or dementia.
*
Includes MCI individuals classified as CDR = 0 at their last available ADNI visit (N = 11) Abbreviations: CN, cognitively normal; MCI, mild cognitive impairment; AD, Alzheimer’s disease (dementia); SNAP, suspected non-AD pathology; ATN: amyloid/tau/neurodegeneration classification